Design of potent inhibitors of acetylcholinesterase using morin as the starting compound

Frontiers in Life Science

Volumn 6, Issue 3-4, 2012, Pages 107-117

  Remya, C ^a   Dileep, K V ^a   Tintu, I ^a   Variyar, E J ^a   Sadasivan, C ^a  

^a KANNUR UNIVERSITY   (India)

Author keywords

acetylcholinesterase; AD; flavonols; IFD; morin

Indexed keywords

EID: 84884999740     PISSN: 21553769     EISSN: 21553777     Source Type: Journal    
DOI: 10.1080/21553769.2013.815137     Document Type: Article

References (49)

1. Arias, E, Gallego-Sandín, S, Villarroya, M, García, A G and Lpez, M G. 2005. Unequal Neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SHSY5Y neuroblastoma cells: role of nicotinic receptors. J Pharm Exp Ther., 315: 1346 - 1353. (doi:10.1124/jpet.105.090365)
2. Arikawa, M, Kakinuma, Y, Handa, T, Yamasaki, F and Sato, T. 2011. Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice. PLoS ONE., 6: e20629 doi:10.1371/journal.pone.0020629 (doi:10.1371/journal.pone.0020629)
3. Bon, S, Vigny, M and Massoulie, J. 1979. Asymmetric and globular forms of acetylcholinesterase in mammals and birds. Proc Natl Acad Sci USA., 76: 2546 - 2550. (doi:10.1073/pnas.76.6.2546)
4. Bullock, R. 2004. Future directions in the treatment of Alzheimer's disease. Expert Opin Investig Drugs., 13: 303 - 314. (doi:10.1517/13543784.13.4.303)
5. Carter, D B and Chou, K C. 1998. A model for structure dependent binding of Congo Red to Alzeheimer beta-amyloid fibrils. Neurobiol Aging., 19: 37 - 40. (doi:10.1016/S0197-4580(97)00164-4)
6. Cavalli, A, Bolognesi, M L, Minarini, A, Rosini, M, Tumiatti, V, Recanatini, M and Melchiorre, C. 2008. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem., 51: 347 - 372. (doi:10.1021/jm7009364)
7. Chou, K C. 2004a. Insights from modeling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor. Biochem Biophys Res Commun., 319: 433 - 438. (doi:10.1016/j.bbrc.2004.05.016)
8. Chou, K C. 2004b. Insights from modeling the tertiary structure of BACE2. J Proteome Res., 3: 1069 - 1072. (doi:10.1021/pr049905s)
9. Chou, K C. 2004c. Review: structural bioinformatics and its impact to biomedical science. Curr Med Chem., 11: 2105 - 2134. (doi:10.2174/0929867043364667)
10. Chou, K C. 2005. Modeling the tertiary structure of human cathepsin-E. Biochem Biophys Res Commun., 331: 56 - 60. (doi:10.1016/j.bbrc.2005.03.123)
11. Chou, K C and Howe, W J. 2002. Prediction of the tertiary structure of the beta-secretase zymogen. Biochem Biophys Res Commun., 292: 702 - 708. (doi:10.1006/bbrc.2002.6686)
12. Chou, K C, Wei, D Q, Du, Q S, Sirois, S and Zhong, W Z. 2006. Review: progress in computational approach to drug development against SARS. Curr Med Chem., 13: 3263 - 3270. (doi:10.2174/092986706778773077)
13. Coyle, J T, Price, D L and Delong, M R. 1983. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science., 219: 1184 - 1190. (doi:10.1126/science.6338589)
14. Ellman, G L, Courtney, K D, Andres, V Jr and Featherstone, R M. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol., 7: 88 - 95. (doi:10.1016/0006-2952(61)90145-9)
15. Gu, R X, Gu, H, Xie, Z Y, Wang, J F, Arias, H R, Wei, D Q and Chou, K C. 2009. Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with alpha7 nicotinic acetylcholine receptor. Medicinal Chemistry., 5: 250 - 262. (doi:10.2174/157340609788185909)
16. Guo Ava, J Y, Xie Heidi, Q, Choi Roy, C Y, Zheng Ken, Y Z, Bi Cathy, W C, Xu Sherry, L, Dong Tina, T X and Tsim Karl, W K. 2010. Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro. Chem Biol Interact., 187: 246 - 248. (doi:10.1016/j.cbi.2010.05.002)
17. Harman, D. 1956. Aging: a theory based on free radical and radiation chemistry. J Gerontol., 11: 298 - 300. (doi:10.1093/geronj/11.3.298)
18. Huang, R B, Du, Q S, Wang, C H and Chou, K C. 2008. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem Biophys Res Comm., 377: 1243 - 1247. (doi:10.1016/j.bbrc.2008.10.148)
19. Huang, X, Moir, R D, Tanzi, R E, Bush, A I and Rogers, J T. 2004. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci., 1012: 153 - 163. (doi:10.1196/annals.1306.012)
20. Inestrosa, N C, Alvarez, A, Perez, C A, Moreno, R D, Vicente, M, Linker, C, Casanueva, O I, Soto, C and Garrido, J. 1996. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron., 16: 881 - 891. (doi:10.1016/S0896-6273(00)80108-7)
21. Ishige, K, Schubert, D and Sagara, Y. 2001. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med., 30: 433 - 446. (doi:10.1016/S0891-5849(00)00498-6)
22. Jung, M and Park, M. 2007. Acetylcholinesterase Inhibition by flavonoids from Agrimonia pilosa. Molecules., 12: 2130 - 2139. (doi:10.3390/12092130)
23. Kasa, P, Papp, H, Kasa, P. Jr and Torok, I. 2000. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience., 101: 89 - 100. (doi:10.1016/S0306-4522(00)00335-3)
24. Katalinić, M, Rusak, G, Barović, J D, Šinko, G, Jelić, D, Antolović, R and Kovarik, Z. 2010. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem., 45: 192 (doi:10.1016/j.ejmech.2009.09.041)
25. Khan, M T, Orhan, I, Senol, F S, Kartal, M, Sener, B, Dvorská, M, Smejkal, K and Slapetová, T. 2009. Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. Chem Biol Interact., 181: 389 (doi:10.1016/j.cbi.2009.06.024)
26. Kim, H, Park, B S, Lee, K G, Choi, C Y, Jang, S S, Kim, Y H and Lee, S E. 2005. Effect of naturally occurring compounds on fibril formation and oxidative stress of beta amyloid. J Agric Food Chem., 53: 8541
27. Lemkul, J A and Bevan, D R. 2010. Destabilizing Alzheimer's Abeta (42) protofibrils with morin: mechanistic insights from molecular dynamics simulations. Biochemistry., 49: 3946 (doi:10.1021/bi1000855)
28. Liao, Q H, Gao, Q Z, Wei, J and Chou, K C. 2011. Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). Medicinal Chemistry., 7: 31 (doi:10.2174/157340611794072698)
29. Lovell, M A, Robertson, J D, Teesdale, W J, Campbell, J L and Markesbery, W R. 1998. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci., 158: 52 (doi:10.1016/S0022-510X(98)00092-6)
30. Ma, Y, Wang, S Q, Xu, W R, Wang, R L and Chou, K C. 2012. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One., 7: e38546 (doi:10.1371/journal.pone.0038546)
31. Malešev, D and Kunti, V. 2007. Investigation of metal-flavonoid chelates and the determination of flavonoids via metal-flavonoid complexing reactions. J Serb Chem Soc., 72 (10): 939 (doi:10.2298/JSC0710921M)
32. Munoz-Ruiz, P, Rubio, L, Garcia-Palomero, E, Dorronsoro, I, del Monte-Millan, M, Valenzuela, R, Usan, P, de Austria, C, Bartolini, M, Andrisano, V, Bidon-Chanal, A, Orozco, M, Luque, F J, Medina, M and Martinez, A. 2005. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem., 48: 7233 (doi:10.1021/jm0503289)
33. Ogura, H, Kosasa, T, Kuriya, Y and Yamanishi, Y. 2000. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol., 22: 609 - 613. (doi:10.1358/mf.2000.22.8.701373)
34. Pearlman, D A. 2005. Evaluating the molecular mechanics poisson-Boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. J Med Chem., 48: 7807 (doi:10.1021/jm050306m)
35. Perry, G, Castellani, R J, Hirai, K and Smith, M A. 1998. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis., 1: 55
36. Perry, G, Nunomura, A, Hirai, K, Zhu, X, Perez, M, Avila, J, Castellani, R J, Atwood, C S, Aliev, G, Sayre, L M, Takeda, A and Smith, M A. 2002. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic Biol Med., 33: 1479 (doi:10.1016/S0891-5849(02)01113-9)
37. Pietta, P G. 2000. Flavonoids as antioxidants. J Nat Prod., 63: 1035 - 1042. (doi:10.1021/np9904509)
38. Rees, T, Hammond, P I, Soreq, H, Younkin, S and Brimijoin, S. 2003. Acetylcholinesterase promotes betaamyloid plaques in cerebral cortex. Neurobiol Aging., 24: 787 (doi:10.1016/S0197-4580(02)00230-0)
39. Remya, C, Dileep, K V, Tintu, I, Variyar, E J and Sadasivan, C. 2012. An in silico approach for the identification of inhibitors against Acetylcholinesterase. Med Chem Res., 21: 2787 (doi:10.1007/s00044-011-9814-y)
40. Rosini, M, Andrisano, V, Bartolini, M, Bolognesi, M L, Hrelia, P, Minarini, A, Tarozzi, A and Melchiorre, C. 2005. Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem., 48: 363 (doi:10.1021/jm049112h)
41. Selkoe, D J. 2001. Alzheimer's disease: genes, proteins and therapy. Phys Rev., 81: 766
42. Smith, M A, Sayre, L M, Monnier, V M and Perry, G. 1995. Radical AGE-ing in Alzheimer's disease. Trends Neurosci., 18: 172 - 176. (doi:10.1016/0166-2236(95)93897-7)
43. Sussman, J L, Harel, M, Frolow, F, Oefner, C, Goldman, A, Toker, L and Silman, I. 1991. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science., 253: 879 (doi:10.1126/science.1678899)
44. Tabet, N. 2006. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!. Age Ageing., 35: 338 (doi:10.1093/ageing/afl027)
45. Takada, Y, Yonezawa, A, Kume, T, Katsuki, H, Kaneko, S, Sugimoto, H and Akaike, A. 2003. Nicotinic acetylcholine receptor-mediated neuroprotection by Donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharm Exp Ther., 306: 777 (doi:10.1124/jpet.103.050104)
46. Wang, L, Tu, Y C, Lian, T W, Hung, J T, Yen, J H and Wu, M J. 2006. Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem., 54: 9804
47. Zhang, Z T, Cao, X B, Xiong, N, Wang, H C, Huang, J S, Sun, S G and Wang, T. 2010. Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo. Acta Pharm Sinic., 31: 906
48. Zheng, H, Wei, D Q, Zhang, R, Wang, C, Wei, H and Chou, K C. 2007. Screening for new agonists against Alzheimer's disease. Medicinal Chemistry., 3: 493 (doi:10.2174/157340607781745492)
49. Zhu, J T, Choi, R C, Chu, G K, Cheung, A W, Gao, Q T, Li, J, Jiang, Z Y, Dong, T T and Tsim, K W. 2007. Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: a comparison of different flavonoids in activating estrogenic effect and in preventing beta-amyloid-induced cell death. J Agric Food Chem., 55: 2438 - 2445. (doi:10.1021/jf063299z)